Table 2 The comparison of baseline characteristics between the CR and non-CR groups
Baseline characteristics | Â | CR group | Non-CR group | p value | |
|---|---|---|---|---|---|
Number of cases | N | 13 | 13 | Â | |
Age | Median (min–max) | 53 (25–68) | 23 (16–70) | 0.09 | |
Gender—male | N (%) | 4 | 7 | 0.234 | |
Body weight, kg | Median (min–max) | 47 (43.7–68.2) | 55 (37.7–83.3) | 0.48 | |
Duration of disease, month | Median (min–max) | 118 (12–159) | 28 (6–130) | 0.001 | |
Extent of UC (Montreal classification) | Â | Â | Â | 0.42 | |
| Â | left side colitis (E2) | N | 4 | 6 | Â |
| Â | pancolitis (E3) | N | 9 | 7 | Â |
Disease activity | Â | Â | Â | Â | |
|  | pMayo score | Median (IQR) | 6 (6–7) | 7 (5–7) | 0.76 |
|  | MES | Median (IQR) | 2 (2–2) | 2 (2–3) | 0.03 |
Concomitant medication | Â | Â | Â | Â | |
| Â | 5-aminosalicylic acid | N (%) | 12 | 10 | Â |
| Â | Corticosteroid | N (%) | 4 | 3 | 0.658 |
| Â | Immunosuppressant | N (%) | 5 | 8 | 0.239 |
| Â | Anti-TNF-alpha agent | N (%) | 3 | 2 | 0.619 |
Biomarker at entry | Â | Â | Â | Â | |
|  | FC (mg/kg) | Median (IQR) | 15,669 (7280–20,017) | 9496 (1073–14,015) | 0.07 |
|  | WBC count | Median (IQR) | 5980 (4760–6970) | 7290 (5200–8250) | 0.29 |
|  | CRP (mg/dL) | Median (IQR) | 0.66 (0.1–4.56) | 0.36 (0.1–1.26) | 0.53 |